FDA
-
-
-
-
-
-
-
Lilly Completes Acquisition of Loxo Oncology
-
-
-
-
-
-
-
Loxo Oncology (LOXO), Bayer Confirm FDA Approval of Vitrakvi for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion
-
-
-
-
-
-
-
Loxo Oncology Announces Larotrectinib Clinical Update in Patients with TRK Fusion Cancers at the European Society for Medical Oncology 2018 Congress
-
-
-
-
-
-
-
Loxo Oncology (LOXO) Announces Accepted Abstracts at ATA
-
-
-
-
-
-
-
Loxo Oncology (LOXO) Announces Accepted Abstracts at IASLC
-
-
-
-
-
-
-
FDA Accepts Larotrectinib New Drug Application and Grants Priority Review
-
-
-
-
-
-
-
Loxo Oncology (LOXO) Completes Rolling Submission of NDA to FDA for Larotrectinib for Treatment of TRK Fusion Cancer
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

